Egypt Alcohol Addiction Therapeutics Market Analysis

Egypt Alcohol Addiction Therapeutics Market Executive Summary

The Egypt Alcohol Addiction Therapeutics Market is valued at around $2 Mn in 2022 and is projected to reach $4 Mn by 2030, exhibiting a CAGR of 7.8% during the forecast period.

Alcohol Addiction or Alcohol Use Disorder (AUD) is more complex than just an irrational urge to drink. The compulsion to drink persists despite the disease’s chronic nature and complexity, resulting in significant emotional, physical, and social repercussions. Getting this illness isn’t an option, but recovery is possible. Alcohol’s addictive nature, stress, and genetic predisposition can all contribute to its development. Fortunately, there are many treatment options available, each tailored to meet the specific needs of those struggling with alcoholism. Drugs like naltrexone, acamprosate, etc can help manage cravings and withdrawal symptoms, but treatment addresses the underlying psychological issues and develops constructive coping skills. Other than these options, support groups are an important part of recovery. Digital websites and apps for mental wellbeing and emotional support are a booming industry.

In Egypt, alcohol addiction is prevalent, with particular patterns. Younger individuals have greater rates, and as people age, the frequency declines. Compared to females, male students and individuals often have greater rates of alcohol consumption and dependency. The percentage of the population that abuses or is dependent on alcohol varies depending on the population, ranging from 2.7% to 8.9%. The market growth in the country is fuelled by changing societal attitudes, increased middle-class discretionary incomes and the increased government’s efforts to improve healthcare facilities.

EIPMCO has an important market share due to its local distribution of well-known drugs like Campral and Vivitrol. Another domestic manufacturer, Pharos Holding, controls the generic disulfiram market. Other well-known global brands with established brands including Vivitrol, Revia, Campral, and Antabuse, are Alkermes Plc, Teva Pharmaceutical Industries Ltd., and Adial Pharmaceuticals Inc. are also important players in Egypt.

Market Dynamics

Market Drivers

Societal Attitudes are Changing: As people become more aware and educated, the stigma attached to getting treatment for alcoholism is progressively disappearing. The middle class is growing, and with it comes more discretionary means to make private medical choices. Another contributing element is the growing number of people migrating to cities, which exposes them to new social norms and possibly higher rates of alcohol consumption, which increases the demand for treatment services.

Better Facilities for Healthcare Provision: The Ministry of Health in Egypt is working to increase access to addiction treatment services in both ordinary hospitals and facilities specifically designated for the purpose. Specialized facilities for the treatment of alcohol addiction are being established by NGOs and private clinics. To meet the rising demand, more psychologists, addiction counsellors, and psychiatrists are being educated.

Technological Developments: Online therapy programs and virtual consultations are expanding access to treatment, particularly in rural regions. To assist in the healing process and track advancements, mobile applications and web resources are being created. Treatment options may be expanded by the development of novel drugs and treatment techniques, such as extended-release naltrexone implants.

Market Restraints

Social and Traditional Norms: Traditional healers and faith-based methods may be prioritized above modern medical care. Addiction is sometimes misunderstood as a moral failing rather than a medical illness, which can make treatment less accessible. This might discourage people from obtaining any kind of treatment.

Economic Limitations: Private treatment is expensive, and public healthcare resources may be insufficient or overworked when it comes to treating addiction. Access to addiction treatment is further limited by the fact that insurance coverage is sometimes minimal. Furthermore, there may be geographical discrepancies in access in rural regions due to a lack of skilled specialists and specialized facilities.

Lack of Healthcare Professionals: There has always been a shortage of specialists and experts in Egypt's healthcare system. Poor service delivery due to a lack of quality may result from this, especially in rural locations.

Healthcare Policies and Regulatory Landscape

The Ministry of Health and Population is in charge of overseeing Egypt's healthcare policy and is in charge of enforcing healthcare service quality standards and regulating the healthcare system. The Egyptian Drug Authority (EDA) is in charge of pharmaceutical and medical device registration, quality control, and post-market surveillance. It is the country's regulating agency in these areas. In addition, the EDA is involved in medication pricing and reimbursement. It also inspects pharmaceutical plants to make sure that acceptable manufacturing procedures are followed. With an emphasis on expanding patient safety and enhancing access to healthcare services, Egypt has been enacting healthcare reforms in recent years to improve the effectiveness and efficacy of its healthcare system. Additionally, the government has been attempting to make its regulatory system stronger in order to conform to international standards of best practice.

Competitive Landscape

Key Players

• Alkermes
• Teva Pharmaceuticals
• Addex Therapeutics
• Opiant Pharmaceuticals
• GlaxoSmithKline (GSK)
• Merck & Co.
• Pharos Holding
• Egypharm
• Amoun Pharmaceuticals
• Egyptian International Pharmaceutical Marketing Co. (EIPMCO)